{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:16:17Z","timestamp":1791994577744,"version":"4.4.0"},"reference-count":172,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,12,29]],"date-time":"2023-12-29T00:00:00Z","timestamp":1703808000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,12,29]],"date-time":"2023-12-29T00:00:00Z","timestamp":1703808000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100006470","name":"Aristotle University of Thessaloniki","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006470","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1007\/s40257-023-00832-1","type":"journal-article","created":{"date-parts":[[2023,12,29]],"date-time":"2023-12-29T08:02:17Z","timestamp":1703836937000},"page":"195-212","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":61,"title":["Advancements in Bullous Pemphigoid Treatment: A Comprehensive Pipeline Update"],"prefix":"10.1007","volume":"25","author":[{"given":"Meropi","family":"Karakioulaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kilian","family":"Eyerich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aikaterini","family":"Patsatsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,29]]},"reference":[{"issue":"3","key":"832_CR1","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1586\/1744666X.2016.1123092","volume":"12","author":"N van Beek","year":"2016","unstructured":"van Beek N, et al. IgE-mediated mechanisms in bullous pemphigoid and other autoimmune bullous diseases. Expert Rev Clin Immunol. 2016;12(3):267\u201377.","journal-title":"Expert Rev Clin Immunol"},{"issue":"9863","key":"832_CR2","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/S0140-6736(12)61140-4","volume":"381","author":"E Schmidt","year":"2013","unstructured":"Schmidt E, Zillikens D. Pemphigoid diseases. Lancet. 2013;381(9863):320\u201332.","journal-title":"Lancet"},{"issue":"5","key":"832_CR3","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.autrev.2017.03.010","volume":"16","author":"IS Bagci","year":"2017","unstructured":"Bagci IS, et al. Bullous pemphigoid. Autoimmun Rev. 2017;16(5):445\u201355.","journal-title":"Autoimmun Rev"},{"issue":"1","key":"832_CR4","first-page":"72","volume":"99","author":"K Kridin","year":"2019","unstructured":"Kridin K, Shihade W, Bergman R. Mortality in patients with bullous pemphigoid: a retrospective cohort study, systematic review and meta-analysis. Acta Derm Venereol. 2019;99(1):72\u20137.","journal-title":"Acta Derm Venereol"},{"issue":"9","key":"832_CR5","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1111\/1346-8138.14503","volume":"45","author":"K Kridin","year":"2018","unstructured":"Kridin K, et al. Mortality in bullous pemphigoid: a systematic review and meta-analysis of standardized mortality ratios. J Dermatol. 2018;45(9):1094\u2013100.","journal-title":"J Dermatol"},{"issue":"11","key":"832_CR6","doi-asserted-by":"publisher","first-page":"2844","DOI":"10.3390\/biomedicines10112844","volume":"10","author":"GM D'Agostino","year":"2022","unstructured":"D'Agostino GM, et al. Bullous pemphygoid and novel therapeutic approaches. Biomedicines. 2022;10(11):2844.","journal-title":"Biomedicines"},{"issue":"2","key":"832_CR7","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1590\/abd1806-4841.20199007","volume":"94","author":"D Miyamoto","year":"2019","unstructured":"Miyamoto D, et al. Bullous pemphigoid. An Bras Dermatol. 2019;94(2):133\u201346.","journal-title":"An Bras Dermatol"},{"issue":"5","key":"832_CR8","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1016\/j.jaad.2019.11.018","volume":"82","author":"ZT Chai","year":"2020","unstructured":"Chai ZT, et al. Diabetes mellitus and hyperglycemic complications in bullous pemphigoid. J Am Acad Dermatol. 2020;82(5):1234\u20137.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"832_CR9","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1111\/bjd.15405","volume":"176","author":"L Kibsgaard","year":"2017","unstructured":"Kibsgaard L, et al. Increased frequency of multiple sclerosis among patients with bullous pemphigoid: a population-based cohort study on comorbidities anchored around the diagnosis of bullous pemphigoid. Br J Dermatol. 2017;176(6):1486\u201391.","journal-title":"Br J Dermatol"},{"issue":"5","key":"832_CR10","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s00403-020-02100-2","volume":"313","author":"S Lee","year":"2021","unstructured":"Lee S, et al. Association of bullous pemphigoid and comorbid health conditions: a case-control study. Arch Dermatol Res. 2021;313(5):327\u201332.","journal-title":"Arch Dermatol Res"},{"key":"832_CR11","doi-asserted-by":"crossref","unstructured":"Baum, S., et al., Prevalence, Spectrum and Clinical Implications of Malignancies in Patients with Bullous Pemphigoid. Acta Derm Venereol, 2023. 103:adv00888.","DOI":"10.2340\/actadv.v103.3979"},{"issue":"1","key":"832_CR12","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.jaad.2022.02.036","volume":"87","author":"A Salemme","year":"2022","unstructured":"Salemme A, et al. Gliptin-associated bullous pemphigoid shows peculiar features of anti-BP180 and -BP230 humoral response: Results of a multicenter study. J Am Acad Dermatol. 2022;87(1):56\u201363.","journal-title":"J Am Acad Dermatol"},{"key":"832_CR13","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.3389\/fimmu.2019.01238","volume":"10","author":"K Tasanen","year":"2019","unstructured":"Tasanen K, Varpuluoma O, Nishie W. Dipeptidyl Peptidase-4 Inhibitor-Associated Bullous Pemphigoid. Front Immunol. 2019;10:1238.","journal-title":"Front Immunol"},{"issue":"10","key":"832_CR14","doi-asserted-by":"publisher","first-page":"2856","DOI":"10.3390\/jcm11102856","volume":"11","author":"M Afarideh","year":"2022","unstructured":"Afarideh M, Borucki R, Werth VP. A review of the immunologic pathways involved in bullous pemphigoid and novel therapeutic targets. J Clin Med. 2022;11(10):2856.","journal-title":"J Clin Med"},{"issue":"7","key":"832_CR15","doi-asserted-by":"publisher","first-page":"e418","DOI":"10.1111\/jdv.17228","volume":"35","author":"M Kasperkiewicz","year":"2021","unstructured":"Kasperkiewicz M, et al. COVID-19 pandemic and autoimmune bullous diseases: a cross-sectional study of the International Pemphigus and Pemphigoid Foundation. J Eur Acad Dermatol Venereol. 2021;35(7):e418\u201321.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"832_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.841506","volume":"9","author":"CA Maronese","year":"2022","unstructured":"Maronese CA, et al. Bullous pemphigoid associated with COVID-19 vaccines: an Italian Multicentre Study. Front Med (Lausanne). 2022;9: 841506.","journal-title":"Front Med (Lausanne)"},{"issue":"1\u20132","key":"832_CR17","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s12016-007-0030-y","volume":"33","author":"M Kasperkiewicz","year":"2007","unstructured":"Kasperkiewicz M, Zillikens D. The pathophysiology of bullous pemphigoid. Clin Rev Allergy Immunol. 2007;33(1\u20132):67\u201377.","journal-title":"Clin Rev Allergy Immunol"},{"key":"832_CR18","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1146\/annurev-pathol-012615-044313","volume":"11","author":"CM Hammers","year":"2016","unstructured":"Hammers CM, Stanley JR. Mechanisms of disease: pemphigus and bullous pemphigoid. Annu Rev Pathol. 2016;11:175\u201397.","journal-title":"Annu Rev Pathol"},{"key":"832_CR19","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.3389\/fimmu.2019.01506","volume":"10","author":"G Genovese","year":"2019","unstructured":"Genovese G, et al. New insights into the pathogenesis of bullous pemphigoid: 2019 update. Front Immunol. 2019;10:1506.","journal-title":"Front Immunol"},{"issue":"2","key":"832_CR20","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1001\/archderm.136.2.174","volume":"136","author":"E Schmidt","year":"2000","unstructured":"Schmidt E, et al. Serum levels of autoantibodies to BP180 correlate with disease activity in patients with bullous pemphigoid. Arch Dermatol. 2000;136(2):174\u20138.","journal-title":"Arch Dermatol"},{"issue":"1","key":"832_CR21","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1001\/archdermatol.2007.9","volume":"144","author":"Y Iwata","year":"2008","unstructured":"Iwata Y, et al. Correlation of IgE autoantibody to BP180 with a severe form of bullous pemphigoid. Arch Dermatol. 2008;144(1):41\u20138.","journal-title":"Arch Dermatol"},{"key":"832_CR22","doi-asserted-by":"publisher","first-page":"1115083","DOI":"10.3389\/fimmu.2023.1115083","volume":"14","author":"L Zhang","year":"2023","unstructured":"Zhang L, et al. Bullous pemphigoid: The role of type 2 inflammation in its pathogenesis and the prospect of targeted therapy. Front Immunol. 2023;14:1115083.","journal-title":"Front Immunol"},{"issue":"1","key":"832_CR23","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s00403-017-1789-1","volume":"310","author":"AH Saniklidou","year":"2018","unstructured":"Saniklidou AH, et al. IgE autoantibodies and their association with the disease activity and phenotype in bullous pemphigoid: a systematic review. Arch Dermatol Res. 2018;310(1):11\u201328.","journal-title":"Arch Dermatol Res"},{"issue":"11","key":"832_CR24","doi-asserted-by":"publisher","first-page":"2216","DOI":"10.1016\/j.clinthera.2017.09.011","volume":"39","author":"JB Rice","year":"2017","unstructured":"Rice JB, et al. Long-term systemic corticosteroid exposure: a systematic literature review. Clin Ther. 2017;39(11):2216\u201329.","journal-title":"Clin Ther"},{"issue":"5","key":"832_CR25","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1056\/NEJMoa011592","volume":"346","author":"P Joly","year":"2002","unstructured":"Joly P, et al. A comparison of oral and topical corticosteroids in patients with bullous pemphigoid. N Engl J Med. 2002;346(5):321\u20137.","journal-title":"N Engl J Med"},{"issue":"4","key":"832_CR26","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1111\/bjd.13717","volume":"172","author":"C Feliciani","year":"2015","unstructured":"Feliciani C, et al. Management of bullous pemphigoid: the European Dermatology Forum consensus in collaboration with the European Academy of Dermatology and Venereology. Br J Dermatol. 2015;172(4):867\u201377.","journal-title":"Br J Dermatol"},{"key":"832_CR27","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.jdin.2022.07.005","volume":"9","author":"FAP Zeng","year":"2022","unstructured":"Zeng FAP, et al. Side effects of steroid-sparing agents in patients with bullous pemphigoid and pemphigus: a systematic review. JAAD Int. 2022;9:33\u201343.","journal-title":"JAAD Int."},{"issue":"7","key":"832_CR28","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1001\/archderm.144.7.946-a","volume":"144","author":"JC Bystryn","year":"2008","unstructured":"Bystryn JC. Comparative effectiveness of azathioprine or mycophenolate mofetil as an adjuvant for the treatment of bullous pemphigoid. Arch Dermatol. 2008;144(7):946.","journal-title":"Arch Dermatol"},{"issue":"6","key":"832_CR29","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1001\/archderm.1994.01690060083010","volume":"130","author":"DP Fivenson","year":"1994","unstructured":"Fivenson DP, et al. Nicotinamide and tetracycline therapy of bullous pemphigoid. Arch Dermatol. 1994;130(6):753\u20138.","journal-title":"Arch Dermatol"},{"issue":"4","key":"832_CR30","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.3390\/jcm12041638","volume":"12","author":"M Wojtczak","year":"2023","unstructured":"Wojtczak M, et al. Can methotrexate be employed as monotherapy for bullous pemphigoid? Analysis of efficiency and tolerance of methotrexate treatment in patients with bullous pemphigoid. J Clin Med. 2023;12(4):1638.","journal-title":"J Clin Med"},{"issue":"6","key":"832_CR31","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1111\/j.1365-2133.2011.10531.x","volume":"165","author":"A Du-Thanh","year":"2011","unstructured":"Du-Thanh A, et al. Combined treatment with low-dose methotrexate and initial short-term superpotent topical steroids in bullous pemphigoid: an open, multicentre, retrospective study. Br J Dermatol. 2011;165(6):1337\u201343.","journal-title":"Br J Dermatol"},{"issue":"4","key":"832_CR32","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/S0190-9622(96)80085-5","volume":"34","author":"F Bouscarat","year":"1996","unstructured":"Bouscarat F, et al. Treatment of bullous pemphigoid with dapsone: retrospective study of thirty-six cases. J Am Acad Dermatol. 1996;34(4):683\u20134.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"832_CR33","first-page":"309","volume":"113","author":"H Barthelemy","year":"1986","unstructured":"Barthelemy H, et al. Cyclosporin in the treatment of bullous pemphigoid: preliminary study. Ann Dermatol Venereol. 1986;113(4):309\u201313.","journal-title":"Ann Dermatol Venereol"},{"issue":"2","key":"832_CR34","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s40257-018-0401-6","volume":"20","author":"N Kremer","year":"2019","unstructured":"Kremer N, et al. Rituximab and omalizumab for the treatment of bullous pemphigoid: a systematic review of the literature. Am J Clin Dermatol. 2019;20(2):209\u201316.","journal-title":"Am J Clin Dermatol"},{"issue":"2","key":"832_CR35","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1080\/09546634.2020.1782325","volume":"33","author":"PM Garrido","year":"2022","unstructured":"Garrido PM, et al. Emerging treatments for bullous pemphigoid. J Dermatolog Treat. 2022;33(2):649\u201361.","journal-title":"J Dermatolog Treat"},{"issue":"10","key":"832_CR36","doi-asserted-by":"publisher","first-page":"4658","DOI":"10.1073\/pnas.1001074107","volume":"107","author":"H Huang","year":"2010","unstructured":"Huang H, Benoist C, Mathis D. Rituximab specifically depletes short-lived autoreactive plasma cells in a mouse model of inflammatory arthritis. Proc Natl Acad Sci U S A. 2010;107(10):4658\u201363.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"832_CR37","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.clindermatol.2019.07.023","volume":"38","author":"RM Thomas","year":"2020","unstructured":"Thomas RM, Colon A, Motaparthi K. Rituximab in autoimmune pemphigoid diseases: indications, optimized regimens, and practice gaps. Clin Dermatol. 2020;38(3):384\u201396.","journal-title":"Clin Dermatol"},{"issue":"15","key":"832_CR38","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1007\/s40265-018-0976-5","volume":"78","author":"KT Amber","year":"2018","unstructured":"Amber KT, et al. Targeted therapies for autoimmune bullous diseases: current status. Drugs. 2018;78(15):1527\u201348.","journal-title":"Drugs"},{"issue":"1","key":"832_CR39","doi-asserted-by":"publisher","first-page":"3525","DOI":"10.1038\/s41598-019-40203-7","volume":"9","author":"N Berkani","year":"2019","unstructured":"Berkani N, et al. B-cell depletion induces a shift in self antigen specific B-cell repertoire and cytokine pattern in patients with bullous pemphigoid. Sci Rep. 2019;9(1):3525.","journal-title":"Sci Rep"},{"issue":"1","key":"832_CR40","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.jaad.2019.03.049","volume":"81","author":"M Polansky","year":"2019","unstructured":"Polansky M, et al. Rituximab therapy in patients with bullous pemphigoid: a retrospective study of 20 patients. J Am Acad Dermatol. 2019;81(1):179\u201386.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"832_CR41","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1016\/j.jaad.2019.11.023","volume":"82","author":"N Tovanabutra","year":"2020","unstructured":"Tovanabutra N, Payne AS. Clinical outcome and safety of rituximab therapy for pemphigoid diseases. J Am Acad Dermatol. 2020;82(5):1237\u20139.","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"832_CR42","doi-asserted-by":"publisher","first-page":"2786","DOI":"10.1038\/jid.2013.236","volume":"133","author":"RP Hall 3rd","year":"2013","unstructured":"Hall RP 3rd, et al. Association of serum B-cell activating factor level and proportion of memory and transitional B cells with clinical response after rituximab treatment of bullous pemphigoid patients. J Invest Dermatol. 2013;133(12):2786\u20138.","journal-title":"J Invest Dermatol"},{"key":"832_CR43","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.973702","volume":"13","author":"C Papara","year":"2022","unstructured":"Papara C, et al. The relevance of complement in pemphigoid diseases: a critical appraisal. Front Immunol. 2022;13: 973702.","journal-title":"Front Immunol"},{"key":"832_CR44","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.3389\/fimmu.2019.01477","volume":"10","author":"G Edwards","year":"2019","unstructured":"Edwards G, et al. Complement activation in autoimmune bullous dermatoses: a comprehensive review. Front Immunol. 2019;10:1477.","journal-title":"Front Immunol"},{"key":"832_CR45","doi-asserted-by":"publisher","first-page":"2687","DOI":"10.3389\/fimmu.2018.02687","volume":"9","author":"RM Chiorean","year":"2018","unstructured":"Chiorean RM, et al. Complement-activating capacity of autoantibodies correlates with disease activity in bullous pemphigoid patients. Front Immunol. 2018;9:2687.","journal-title":"Front Immunol"},{"issue":"3","key":"832_CR46","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1159\/000106585","volume":"215","author":"N Wallet-Faber","year":"2007","unstructured":"Wallet-Faber N, et al. Epidermolysis bullosa acquisita following bullous pemphigoid, successfully treated with the anti-CD20 monoclonal antibody rituximab. Dermatology. 2007;215(3):252\u20135.","journal-title":"Dermatology"},{"issue":"4","key":"832_CR47","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1111\/1346-8138.16668","volume":"50","author":"Q Chen","year":"2023","unstructured":"Chen Q, et al. Three cases of refractory bullous pemphigoid in the elderly treated successfully with ultra-low-dose rituximab. J Dermatol. 2023;50(4):561\u20134.","journal-title":"J Dermatol"},{"issue":"1","key":"832_CR48","doi-asserted-by":"publisher","first-page":"T62","DOI":"10.1016\/j.ad.2021.10.018","volume":"114","author":"C Suarez-Carantona","year":"2023","unstructured":"Suarez-Carantona C, et al. Low-dose rituximab for bullous pemphigoid. Protocol and single-center experience. Actas Dermosifiliogr. 2023;114(1):T62\u20138.","journal-title":"Actas Dermosifiliogr"},{"issue":"1","key":"832_CR49","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1111\/bjd.13633","volume":"173","author":"YT Cho","year":"2015","unstructured":"Cho YT, Chu CY, Wang LF. First-line combination therapy with rituximab and corticosteroids provides a high complete remission rate in moderate-to-severe bullous pemphigoid. Br J Dermatol. 2015;173(1):302\u20134.","journal-title":"Br J Dermatol"},{"issue":"3","key":"832_CR50","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1016\/j.jaci.2014.11.001","volume":"135","author":"F Annunziato","year":"2015","unstructured":"Annunziato F, Romagnani C, Romagnani S. The 3 major types of innate and adaptive cell-mediated effector immunity. J Allergy Clin Immunol. 2015;135(3):626\u201335.","journal-title":"J Allergy Clin Immunol"},{"issue":"6093","key":"832_CR51","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1126\/science.1221064","volume":"337","author":"B Pulendran","year":"2012","unstructured":"Pulendran B, Artis D. New paradigms in type 2 immunity. Science. 2012;337(6093):431\u20135.","journal-title":"Science"},{"issue":"5","key":"832_CR52","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/jdv.14673","volume":"32","author":"K Eyerich","year":"2018","unstructured":"Eyerich K, Eyerich S. Immune response patterns in non-communicable inflammatory skin diseases. J Eur Acad Dermatol Venereol. 2018;32(5):692\u2013703.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"11","key":"832_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2020.102661","volume":"19","author":"H Fang","year":"2020","unstructured":"Fang H, Li Q, Wang G. The role of T cells in pemphigus vulgaris and bullous pemphigoid. Autoimmun Rev. 2020;19(11): 102661.","journal-title":"Autoimmun Rev"},{"issue":"5","key":"832_CR54","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1111\/dth.12327","volume":"29","author":"S Tavakolpour","year":"2016","unstructured":"Tavakolpour S. Dupilumab: a revolutionary emerging drug in atopic dermatitis and its possible role in pemphigus. Dermatol Ther. 2016;29(5):299.","journal-title":"Dermatol Ther"},{"issue":"9","key":"832_CR55","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1111\/1346-8138.16428","volume":"49","author":"S Takamura","year":"2022","unstructured":"Takamura S, Teraki Y. Treatment of bullous pemphigoid with dupilumab: Dupilumab exerts its effect by primarily suppressing T-helper 2 cytokines. J Dermatol. 2022;49(9):845\u201350.","journal-title":"J Dermatol"},{"issue":"2","key":"832_CR56","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1177\/205873929901200202","volume":"12","author":"C Feliciani","year":"1999","unstructured":"Feliciani C, et al. A Th2-like cytokine response is involved in bullous pemphigoid. The role of IL-4 and IL-5 in the pathogenesis of the disease. Int J Immunopathol Pharmacol. 1999;12(2):55\u201361.","journal-title":"Int J Immunopathol Pharmacol"},{"issue":"2","key":"832_CR57","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/S0923-1811(02)00067-1","volume":"30","author":"B Giomi","year":"2002","unstructured":"Giomi B, et al. Th1, Th2 and Th3 cytokines in the pathogenesis of bullous pemphigoid. J Dermatol Sci. 2002;30(2):116\u201328.","journal-title":"J Dermatol Sci"},{"issue":"2","key":"832_CR58","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1111\/cei.12566","volume":"180","author":"WJ Pickford","year":"2015","unstructured":"Pickford WJ, et al. T cell participation in autoreactivity to NC16a epitopes in bullous pemphigoid. Clin Exp Immunol. 2015;180(2):189\u2013200.","journal-title":"Clin Exp Immunol"},{"issue":"9","key":"832_CR59","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0107725","volume":"9","author":"KN Messingham","year":"2014","unstructured":"Messingham KN, et al. Human eosinophils express the high affinity IgE receptor, FcepsilonRI, in bullous pemphigoid. PLoS ONE. 2014;9(9): e107725.","journal-title":"PLoS ONE"},{"issue":"4","key":"832_CR60","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1684\/ejd.2018.3366","volume":"28","author":"E Cozzani","year":"2018","unstructured":"Cozzani E, et al. Immunoglobulin E and bullous pemphigoid. Eur J Dermatol. 2018;28(4):440\u20138.","journal-title":"Eur J Dermatol"},{"issue":"2","key":"832_CR61","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.clim.2006.03.014","volume":"120","author":"S Gounni Abdelilah","year":"2006","unstructured":"Gounni Abdelilah S, et al. Increased expression of Th2-associated chemokines in bullous pemphigoid disease. Role of eosinophils in the production and release of these chemokines. Clin Immunol. 2006;120(2):220\u201331.","journal-title":"Clin Immunol"},{"issue":"3 Suppl 1","key":"832_CR62","doi-asserted-by":"publisher","first-page":"S28","DOI":"10.1016\/j.jaad.2017.12.022","volume":"78","author":"MJ Gooderham","year":"2018","unstructured":"Gooderham MJ, et al. Dupilumab: A review of its use in the treatment of atopic dermatitis. J Am Acad Dermatol. 2018;78(3 Suppl 1):S28\u201336.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"832_CR63","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.jaad.2020.01.089","volume":"83","author":"R Abdat","year":"2020","unstructured":"Abdat R, et al. Dupilumab as a novel therapy for bullous pemphigoid: a multicenter case series. J Am Acad Dermatol. 2020;83(1):46\u201352.","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"832_CR64","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15648","volume":"35","author":"J Yang","year":"2022","unstructured":"Yang J, et al. Dupilumab combined with low-dose systemic steroid therapy improves efficacy and safety for bullous pemphigoid. Dermatol Ther. 2022;35(8): e15648.","journal-title":"Dermatol Ther"},{"key":"832_CR65","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.738907","volume":"12","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, et al. Efficacy and safety of dupilumab in moderate-to-severe bullous pemphigoid. Front Immunol. 2021;12: 738907.","journal-title":"Front Immunol"},{"key":"832_CR66","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.611549","volume":"11","author":"SM Seyed Jafari","year":"2020","unstructured":"Seyed Jafari SM, et al. Case Report: Combination of Omalizumab and Dupilumab for Recalcitrant Bullous Pemphigoid. Front Immunol. 2020;11: 611549.","journal-title":"Front Immunol"},{"key":"832_CR67","doi-asserted-by":"crossref","unstructured":"Bruni M, et al. A case of nivolumab-induced bullous pemphigoid successfully treated with dupilumab. Dermatol Online J. 2022;28(2).","DOI":"10.5070\/D328257396"},{"issue":"8","key":"832_CR68","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15623","volume":"35","author":"SR Pop","year":"2022","unstructured":"Pop SR, Strock D, Smith RJ. Dupilumab for the treatment of pembrolizumab-induced bullous pemphigoid: a case report. Dermatol Ther. 2022;35(8): e15623.","journal-title":"Dermatol Ther"},{"issue":"9","key":"832_CR69","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1001\/jamadermatol.2023.2428","volume":"159","author":"L Zhao","year":"2023","unstructured":"Zhao L, et al. Evaluation of dupilumab in patients with bullous pemphigoid. JAMA Dermatol. 2023;159(9):953\u201360.","journal-title":"JAMA Dermatol"},{"key":"832_CR70","unstructured":"US National Library of Medicine, ClinicalTrials.gov. A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients with Bullous Pemphigoid, NCT04206553. 2019. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04206553."},{"issue":"3","key":"832_CR71","doi-asserted-by":"publisher","first-page":"adv00419","DOI":"10.2340\/00015555-3771","volume":"101","author":"J Pruessmann","year":"2021","unstructured":"Pruessmann J, et al. Immunomodulator galectin-9 is increased in blood and skin of patients with bullous pemphigoid. Acta Derm Venereol. 2021;101(3):adv00419.","journal-title":"Acta Derm Venereol"},{"issue":"4","key":"832_CR72","doi-asserted-by":"publisher","first-page":"464","DOI":"10.2340\/00015555-2581","volume":"97","author":"J Engmann","year":"2017","unstructured":"Engmann J, et al. increased activity and apoptosis of eosinophils in blister fluids, skin and peripheral blood of patients with bullous pemphigoid. Acta Derm Venereol. 2017;97(4):464\u201371.","journal-title":"Acta Derm Venereol"},{"issue":"2","key":"832_CR73","doi-asserted-by":"publisher","first-page":"e236","DOI":"10.1111\/ajd.13547","volume":"62","author":"M Gore Karaali","year":"2021","unstructured":"Gore Karaali M, et al. Tissue eosinophil levels as a marker of disease severity in bullous pemphigoid. Australas J Dermatol. 2021;62(2):e236\u201341.","journal-title":"Australas J Dermatol"},{"issue":"5","key":"832_CR74","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1111\/bjd.16679","volume":"179","author":"K Kridin","year":"2018","unstructured":"Kridin K. Peripheral eosinophilia in bullous pemphigoid: prevalence and influence on the clinical manifestation. Br J Dermatol. 2018;179(5):1141\u20137.","journal-title":"Br J Dermatol"},{"issue":"3\u20134","key":"832_CR75","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1080\/07853890.2020.1742367","volume":"52","author":"Y Liu","year":"2020","unstructured":"Liu Y, et al. Factors associated with the activity and severity of bullous pemphigoid: a review. Ann Med. 2020;52(3\u20134):55\u201362.","journal-title":"Ann Med"},{"issue":"5","key":"832_CR76","doi-asserted-by":"publisher","first-page":"544","DOI":"10.5021\/ad.2018.30.5.544","volume":"30","author":"SH Park","year":"2018","unstructured":"Park SH, et al. Circulating eosinophil and neutrophil counts correlate with disease severity in bullous pemphigoid. Ann Dermatol. 2018;30(5):544\u20139.","journal-title":"Ann Dermatol"},{"issue":"1","key":"832_CR77","first-page":"27","volume":"12","author":"A Frezzolini","year":"2002","unstructured":"Frezzolini A, et al. Increased expression of eotaxin and its specific receptor CCR3 in bullous pemphigoid. Eur J Dermatol. 2002;12(1):27\u201331.","journal-title":"Eur J Dermatol"},{"issue":"4","key":"832_CR78","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1080\/000155500750012162","volume":"80","author":"M Shrikhande","year":"2000","unstructured":"Shrikhande M, et al. Increased coexpression of eotaxin and interleukin 5 in bullous pemphigoid. Acta Derm Venereol. 2000;80(4):277\u201380.","journal-title":"Acta Derm Venereol"},{"issue":"1","key":"832_CR79","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1046\/j.1365-2133.2000.03599.x","volume":"143","author":"M Wakugawa","year":"2000","unstructured":"Wakugawa M, et al. Elevated levels of eotaxin and interleukin-5 in blister fluid of bullous pemphigoid: correlation with tissue eosinophilia. Br J Dermatol. 2000;143(1):112\u20136.","journal-title":"Br J Dermatol"},{"issue":"2","key":"832_CR80","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1111\/j.1365-2249.2011.04464.x","volume":"166","author":"C Gunther","year":"2011","unstructured":"Gunther C, et al. Up-regulation of CCL11 and CCL26 is associated with activated eosinophils in bullous pemphigoid. Clin Exp Immunol. 2011;166(2):145\u201353.","journal-title":"Clin Exp Immunol"},{"issue":"12","key":"832_CR81","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1111\/exd.13782","volume":"27","author":"KT Amber","year":"2018","unstructured":"Amber KT, et al. Mechanisms of pathogenic effects of eosinophil cationic protein and eosinophil-derived neurotoxin on human keratinocytes. Exp Dermatol. 2018;27(12):1322\u20137.","journal-title":"Exp Dermatol"},{"issue":"2","key":"832_CR82","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.cyto.2012.01.009","volume":"58","author":"EA Kelly","year":"2012","unstructured":"Kelly EA, et al. Potent synergistic effect of IL-3 and TNF on matrix metalloproteinase 9 generation by human eosinophils. Cytokine. 2012;58(2):199\u2013206.","journal-title":"Cytokine"},{"issue":"1","key":"832_CR83","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1172\/JCI3693","volume":"105","author":"Z Liu","year":"2000","unstructured":"Liu Z, et al. A critical role for neutrophil elastase in experimental bullous pemphigoid. J Clin Invest. 2000;105(1):113\u201323.","journal-title":"J Clin Invest"},{"issue":"4","key":"832_CR84","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1165\/ajrcmb.16.4.9115757","volume":"16","author":"S Okada","year":"1997","unstructured":"Okada S, et al. Transmigration of eosinophils through basement membrane components in vitro: synergistic effects of platelet-activating factor and eosinophil-active cytokines. Am J Respir Cell Mol Biol. 1997;16(4):455\u201363.","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"8","key":"832_CR85","doi-asserted-by":"publisher","first-page":"766","DOI":"10.2340\/00015555-2951","volume":"98","author":"U Rudrich","year":"2018","unstructured":"Rudrich U, et al. Eosinophils are a major source of interleukin-31 in bullous pemphigoid. Acta Derm Venereol. 2018;98(8):766\u201371.","journal-title":"Acta Derm Venereol"},{"key":"832_CR86","unstructured":"US National Library of Medicine, ClinicalTrials.gov. Evaluation of Safety, Efficacy and Pharmacodynamic Effect of Bertilimumab in Patients With Bullous Pemphigoid. 2018; Available at: https:\/\/clinicaltrials.gov\/study\/NCT02226146."},{"key":"832_CR87","unstructured":"US National Library of Medicine, ClinicalTrials.gov. A Study to Assess the Therapeutic Effect and Safety of Adjunctive AKST4290 in Subjects With Bullous Pemphigoid. 2023. Available at: https:\/\/clinicaltrials.gov\/study\/NCT04499235?a=4."},{"issue":"10","key":"832_CR88","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1007\/s40265-022-01741-z","volume":"82","author":"SJ Keam","year":"2022","unstructured":"Keam SJ. Nemolizumab: FIRST APPROVAL. Drugs. 2022;82(10):1143\u201350.","journal-title":"Drugs"},{"issue":"5334","key":"832_CR89","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1126\/science.277.5334.2005","volume":"277","author":"F Sallusto","year":"1997","unstructured":"Sallusto F, Mackay CR, Lanzavecchia A. Selective expression of the eotaxin receptor CCR3 by human T helper 2 cells. Science. 1997;277(5334):2005\u20137.","journal-title":"Science"},{"issue":"8 Pt 1","key":"832_CR90","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1164\/ajrccm.164.8.2010002","volume":"164","author":"RG Stirling","year":"2001","unstructured":"Stirling RG, et al. Interleukin-5 induces CD34(+) eosinophil progenitor mobilization and eosinophil CCR3 expression in asthma. Am J Respir Crit Care Med. 2001;164(8 Pt 1):1403\u20139.","journal-title":"Am J Respir Crit Care Med"},{"issue":"1\u20132","key":"832_CR91","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s004030050272","volume":"290","author":"L D'Auria","year":"1998","unstructured":"D\u2019Auria L, et al. IL-5 levels in the serum and blister fluid of patients with bullous pemphigoid: correlations with eosinophil cationic protein, RANTES, IgE and disease severity. Arch Dermatol Res. 1998;290(1\u20132):25\u20137.","journal-title":"Arch Dermatol Res"},{"issue":"2","key":"832_CR92","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1002\/art.41943","volume":"74","author":"A Bettiol","year":"2022","unstructured":"Bettiol A, et al. Mepolizumab for eosinophilic granulomatosis with polyangiitis: a European multicenter observational study. Arthritis Rheumatol. 2022;74(2):295\u2013306.","journal-title":"Arthritis Rheumatol"},{"issue":"10","key":"832_CR93","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/S2213-2600(21)00097-7","volume":"9","author":"JK Han","year":"2021","unstructured":"Han JK, et al. Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med. 2021;9(10):1141\u201353.","journal-title":"Lancet Respir Med"},{"issue":"13","key":"832_CR94","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1056\/NEJMoa1403290","volume":"371","author":"HG Ortega","year":"2014","unstructured":"Ortega HG, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014;371(13):1198\u2013207.","journal-title":"N Engl J Med"},{"issue":"9842","key":"832_CR95","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/S0140-6736(12)60988-X","volume":"380","author":"ID Pavord","year":"2012","unstructured":"Pavord ID, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet. 2012;380(9842):651\u20139.","journal-title":"Lancet"},{"issue":"20","key":"832_CR96","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1056\/NEJMoa1702079","volume":"376","author":"ME Wechsler","year":"2017","unstructured":"Wechsler ME, et al. Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis. N Engl J Med. 2017;376(20):1921\u201332.","journal-title":"N Engl J Med"},{"issue":"3","key":"832_CR97","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1111\/all.13950","volume":"75","author":"D Simon","year":"2020","unstructured":"Simon D, et al. Mepolizumab failed to affect bullous pemphigoid: a randomized, placebo-controlled, double-blind phase 2 pilot study. Allergy. 2020;75(3):669\u201372.","journal-title":"Allergy"},{"issue":"5","key":"832_CR98","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/S2213-2600(15)00042-9","volume":"3","author":"M Castro","year":"2015","unstructured":"Castro M, et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir Med. 2015;3(5):355\u201366.","journal-title":"Lancet Respir Med"},{"issue":"7","key":"832_CR99","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1007\/s40265-017-0740-2","volume":"77","author":"ED Deeks","year":"2017","unstructured":"Deeks ED, Brusselle G. Reslizumab in eosinophilic asthma: a review. Drugs. 2017;77(7):777\u201384.","journal-title":"Drugs"},{"issue":"8","key":"832_CR100","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1007\/s40265-016-0583-2","volume":"76","author":"A Markham","year":"2016","unstructured":"Markham A. Reslizumab: first global approval. Drugs. 2016;76(8):907\u201311.","journal-title":"Drugs"},{"issue":"1","key":"832_CR101","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s13223-021-00619-1","volume":"17","author":"HI Rhyou","year":"2021","unstructured":"Rhyou HI, Han SH, Nam YH. Successful induction treatment of bullous pemphigoid using reslizumab: a case report. Allergy Asthma Clin Immunol. 2021;17(1):117.","journal-title":"Allergy Asthma Clin Immunol"},{"key":"832_CR102","doi-asserted-by":"publisher","first-page":"135","DOI":"10.3389\/fmed.2017.00135","volume":"4","author":"D Bagnasco","year":"2017","unstructured":"Bagnasco D, et al. Anti-interleukin 5 (IL-5) and IL-5Ra biological drugs: efficacy, safety, and future perspectives in severe eosinophilic asthma. Front Med (Lausanne). 2017;4:135.","journal-title":"Front Med (Lausanne)"},{"issue":"10056","key":"832_CR103","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.1016\/S0140-6736(16)31322-8","volume":"388","author":"JM FitzGerald","year":"2016","unstructured":"FitzGerald JM, et al. Benralizumab, an anti-interleukin-5 receptor alpha monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2016;388(10056):2128\u201341.","journal-title":"Lancet"},{"key":"832_CR104","unstructured":"US National Library of Medicine, ClinicalTrials.gov. A Study to Investigate the Use of Benralizumab in Patients With Bullous Pemphigoid. (FJORD). NCT04612790. 2023. Available at: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT04612790."},{"issue":"2","key":"832_CR105","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1111\/j.1365-2133.2008.08858.x","volume":"160","author":"SK Dresow","year":"2009","unstructured":"Dresow SK, et al. IgE autoantibodies against the intracellular domain of BP180. Br J Dermatol. 2009;160(2):429\u201332.","journal-title":"Br J Dermatol"},{"issue":"2","key":"832_CR106","first-page":"193","volume":"18","author":"TT Provost","year":"1974","unstructured":"Provost TT, Tomasi Jr. TB. Immunopathology of bullous pemphigoid Basement membrane deposition of IgE, alternate pathway components and fibrin. Clin Exp Immunol. 1974;18(2):193\u2013200.","journal-title":"Clin Exp Immunol"},{"issue":"2","key":"832_CR107","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1089\/hyb.2011.0102","volume":"31","author":"KA Messingham","year":"2012","unstructured":"Messingham KA, et al. Functional characterization of an IgE-class monoclonal antibody specific for the bullous pemphigoid autoantigen, BP180. Hybridoma (Larchmt). 2012;31(2):111\u20137.","journal-title":"Hybridoma (Larchmt)"},{"issue":"2","key":"832_CR108","doi-asserted-by":"publisher","first-page":"191","DOI":"10.2340\/00015555-2101","volume":"96","author":"M Kalowska","year":"2016","unstructured":"Kalowska M, et al. Enzyme-linked immunoassay index for anti-NC16a IgG and IgE auto-antibodies correlates with severity and activity of bullous pemphigoid. Acta Derm Venereol. 2016;96(2):191\u20136.","journal-title":"Acta Derm Venereol"},{"issue":"5","key":"832_CR109","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1111\/bjd.18364","volume":"182","author":"A Kamata","year":"2020","unstructured":"Kamata A, et al. Basement membrane zone IgE deposition is associated with bullous pemphigoid disease severity and treatment results. Br J Dermatol. 2020;182(5):1221\u20137.","journal-title":"Br J Dermatol"},{"issue":"1","key":"832_CR110","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1001\/jamadermatol.2016.3357","volume":"153","author":"N van Beek","year":"2017","unstructured":"van Beek N, et al. Correlation of serum levels of IgE autoantibodies against BP180 with bullous pemphigoid disease activity. JAMA Dermatol. 2017;153(1):30\u20138.","journal-title":"JAMA Dermatol"},{"issue":"3","key":"832_CR111","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.clim.2012.02.003","volume":"143","author":"L Fania","year":"2012","unstructured":"Fania L, et al. IgE recognition of bullous pemphigoid (BP)180 and BP230 in BP patients and elderly individuals with pruritic dermatoses. Clin Immunol. 2012;143(3):236\u201345.","journal-title":"Clin Immunol"},{"issue":"1","key":"832_CR112","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1111\/bjd.15114","volume":"177","author":"T Hashimoto","year":"2017","unstructured":"Hashimoto T, et al. Detection of IgE autoantibodies to BP180 and BP230 and their relationship to clinical features in bullous pemphigoid. Br J Dermatol. 2017;177(1):141\u201351.","journal-title":"Br J Dermatol"},{"issue":"3","key":"832_CR113","doi-asserted-by":"publisher","first-page":"236","DOI":"10.2340\/0001555577236","volume":"77","author":"E Cozzani","year":"1997","unstructured":"Cozzani E, et al. Anti-230 kDa circulating IgE in bullous pemphigoid: relationship with disease activity. Acta Derm Venereol. 1997;77(3):236.","journal-title":"Acta Derm Venereol"},{"issue":"2","key":"832_CR114","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.jdermsci.2007.08.008","volume":"49","author":"N Ishiura","year":"2008","unstructured":"Ishiura N, et al. Serum levels of IgE anti-BP180 and anti-BP230 autoantibodies in patients with bullous pemphigoid. J Dermatol Sci. 2008;49(2):153\u201361.","journal-title":"J Dermatol Sci"},{"issue":"9","key":"832_CR115","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1111\/1346-8138.15952","volume":"48","author":"YC Shih","year":"2021","unstructured":"Shih YC, et al. BP230 IgE autoantibodies in topical-steroid-resistant bullous pemphigoid. J Dermatol. 2021;48(9):1372\u201380.","journal-title":"J Dermatol"},{"issue":"11","key":"832_CR116","doi-asserted-by":"publisher","first-page":"4187","DOI":"10.4049\/jimmunol.1601476","volume":"197","author":"T Kawakami","year":"2016","unstructured":"Kawakami T, Blank U. From IgE to Omalizumab. J Immunol. 2016;197(11):4187\u201392.","journal-title":"J Immunol"},{"issue":"10","key":"832_CR117","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1111\/jdv.13758","volume":"30","author":"G Balakirski","year":"2016","unstructured":"Balakirski G, et al. Successful treatment of bullous pemphigoid with omalizumab as corticosteroid-sparing agent: report of two cases and review of literature. J Eur Acad Dermatol Venereol. 2016;30(10):1778\u201382.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"832_CR118","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.clim.2018.12.015","volume":"198","author":"T James","year":"2019","unstructured":"James T, et al. IgE blockade in autoimmunity: Omalizumab induced remission of bullous pemphigoid. Clin Immunol. 2019;198:54\u20136.","journal-title":"Clin Immunol"},{"issue":"3","key":"832_CR119","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/j.jaad.2014.04.053","volume":"71","author":"KK Yu","year":"2014","unstructured":"Yu KK, et al. Omalizumab therapy for bullous pemphigoid. J Am Acad Dermatol. 2014;71(3):468\u201374.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"832_CR120","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.annder.2020.08.053","volume":"148","author":"M Sarrazin","year":"2021","unstructured":"Sarrazin M, Jouen F, Duvert-Lehembre S. Refractory bullous pemphigoid with IgE anti-BP230 and IgG anti-p200 antibodies successfully treated with omalizumab. Ann Dermatol Venereol. 2021;148(1):60\u20132.","journal-title":"Ann Dermatol Venereol"},{"issue":"7","key":"832_CR121","doi-asserted-by":"publisher","first-page":"e469","DOI":"10.1111\/jdv.17229","volume":"35","author":"D De","year":"2021","unstructured":"De D, et al. Omalizumab: an underutilized treatment option in bullous pemphigoid patients with co-morbidities. J Eur Acad Dermatol Venereol. 2021;35(7):e469\u201372.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"832_CR122","doi-asserted-by":"publisher","first-page":"577","DOI":"10.4103\/0378-6323.183628","volume":"82","author":"MZ Gonul","year":"2016","unstructured":"Gonul MZ, et al. Bullous pemphigoid successfully treated with omalizumab. Indian J Dermatol Venereol Leprol. 2016;82(5):577\u20139.","journal-title":"Indian J Dermatol Venereol Leprol"},{"issue":"11","key":"832_CR123","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1001\/archdermatol.2012.1604","volume":"148","author":"VA London","year":"2012","unstructured":"London VA, et al. Successful treatment of bullous pemphigoid with omalizumab. Arch Dermatol. 2012;148(11):1241\u20133.","journal-title":"Arch Dermatol"},{"issue":"5","key":"832_CR124","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1111\/j.1365-2133.2011.10748.x","volume":"166","author":"C Dufour","year":"2012","unstructured":"Dufour C, et al. Successful management of severe infant bullous pemphigoid with omalizumab. Br J Dermatol. 2012;166(5):1140\u20132.","journal-title":"Br J Dermatol"},{"issue":"2","key":"832_CR125","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1684\/ejd.2019.3499","volume":"29","author":"R Maglie","year":"2019","unstructured":"Maglie R, et al. Dramatic exacerbation of bullous pemphigoid following rituximab and successful treatment with omalizumab. Eur J Dermatol. 2019;29(2):213\u20135.","journal-title":"Eur J Dermatol"},{"key":"832_CR126","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.3389\/fimmu.2019.01919","volume":"10","author":"SM Seyed Jafari","year":"2019","unstructured":"Seyed Jafari SM, et al. Effects of omalizumab on FcepsilonRI and IgE expression in lesional skin of bullous pemphigoid. Front Immunol. 2019;10:1919.","journal-title":"Front Immunol"},{"key":"832_CR127","doi-asserted-by":"crossref","unstructured":"Chebani R, et al. Omalizumab in the treatment of bullous pemphigoid resistant to first-line therapy: a French national multicentre retrospective study of 100 patients. Br J Dermatol. 2023;ljad369.","DOI":"10.1093\/bjd\/ljad369"},{"issue":"6","key":"832_CR128","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14160","volume":"33","author":"PM Garrido","year":"2020","unstructured":"Garrido PM, et al. Dipeptidyl-peptidase IV inhibitor-associated bullous pemphigoid efficiently treated with omalizumab. Dermatol Ther. 2020;33(6): e14160.","journal-title":"Dermatol Ther"},{"issue":"2","key":"832_CR129","doi-asserted-by":"publisher","DOI":"10.1111\/dth.12829","volume":"32","author":"C Vico-Alonso","year":"2019","unstructured":"Vico-Alonso C, et al. Omalizumab as an alternative therapeutic tool in the treatment of bullous pemphigoid: a case report. Dermatol Ther. 2019;32(2): e12829.","journal-title":"Dermatol Ther"},{"key":"832_CR130","unstructured":"US National Library of Medicine, ClinicalTrials.gov. An Open-Label Study to Evaluate the Efficacy and Safety of Rituximab Combined with Omalizumab in Patients with Bullous Pemphigoid, NCT04128176. 2019. Available at: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT04128176."},{"issue":"24","key":"832_CR131","first-page":"413","volume":"118","author":"NV Beek","year":"2021","unstructured":"Beek NV, Zillikens D, Schmidt E. Bullous Autoimmune Dermatoses-Clinical Features, Diagnostic Evaluation, and Treatment Options. Dtsch Arztebl Int. 2021;118(24):413\u201320.","journal-title":"Dtsch Arztebl Int"},{"issue":"6","key":"832_CR132","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1111\/exd.12146","volume":"22","author":"H Iwata","year":"2013","unstructured":"Iwata H, Kitajima Y. Bullous pemphigoid: role of complement and mechanisms for blister formation within the lamina lucida. Exp Dermatol. 2013;22(6):381\u20135.","journal-title":"Exp Dermatol"},{"issue":"3","key":"832_CR133","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s12026-008-8028-y","volume":"41","author":"E Lessey","year":"2008","unstructured":"Lessey E, et al. Complement and cutaneous autoimmune blistering diseases. Immunol Res. 2008;41(3):223\u201332.","journal-title":"Immunol Res"},{"key":"832_CR134","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.smim.2018.03.002","volume":"37","author":"CD Sadik","year":"2018","unstructured":"Sadik CD, et al. The critical role of C5a as an initiator of neutrophil-mediated autoimmune inflammation of the joint and skin. Semin Immunol. 2018;37:21\u20139.","journal-title":"Semin Immunol"},{"issue":"15","key":"832_CR135","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.128239","volume":"4","author":"T Sezin","year":"2019","unstructured":"Sezin T, et al. Dual inhibition of complement factor 5 and leukotriene B4 synergistically suppresses murine pemphigoid disease. JCI Insight. 2019;4(15):e128239.","journal-title":"JCI Insight."},{"issue":"14","key":"832_CR136","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1016\/j.intimp.2007.07.006","volume":"7","author":"RG DiScipio","year":"2007","unstructured":"DiScipio RG, Schraufstatter IU. The role of the complement anaphylatoxins in the recruitment of eosinophils. Int Immunopharmacol. 2007;7(14):1909\u201323.","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"832_CR137","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1111\/j.1398-9995.1995.tb02481.x","volume":"50","author":"G Zeck-Kapp","year":"1995","unstructured":"Zeck-Kapp G, et al. Mechanisms of human eosinophil activation by complement protein C5a and platelet-activating factor: similar functional responses are accompanied by different morphologic alterations. Allergy. 1995;50(1):34\u201347.","journal-title":"Allergy"},{"key":"832_CR138","doi-asserted-by":"publisher","first-page":"488","DOI":"10.3389\/fimmu.2018.00488","volume":"9","author":"CM Karsten","year":"2018","unstructured":"Karsten CM, et al. Tissue destruction in bullous pemphigoid can be complement independent and may be mitigated by C5aR2. Front Immunol. 2018;9:488.","journal-title":"Front Immunol"},{"key":"832_CR139","doi-asserted-by":"publisher","first-page":"535","DOI":"10.3389\/fimmu.2018.00535","volume":"9","author":"S Mihai","year":"2018","unstructured":"Mihai S, et al. Specific inhibition of complement activation significantly ameliorates autoimmune blistering disease in mice. Front Immunol. 2018;9:535.","journal-title":"Front Immunol"},{"issue":"6","key":"832_CR140","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1001\/jamadermatol.2022.1156","volume":"158","author":"CD Sadik","year":"2022","unstructured":"Sadik CD, et al. Evaluation of nomacopan for treatment of bullous pemphigoid: a phase 2a nonrandomized controlled trial. JAMA Dermatol. 2022;158(6):641\u20139.","journal-title":"JAMA Dermatol"},{"key":"832_CR141","unstructured":"US National Library of Medicine, ClinicalTrials.gov. Nomacopan Therapy in Adult Patients With Bullous Pemphigoid Receiving Adjunct Oral Corticosteroid Therapy (ARREST-BP) (ARREST-BP). 2021. Available at: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT05061771."},{"key":"832_CR142","unstructured":"US National Library of Medicine, ClinicalTrials.gov. Treatment of Bullous Pemphigoid With Avdoralimab (IPH5401), an Anti-C5aR1 Monoclonal Antibody (IPH). 2020. Available at: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT04563923."},{"key":"832_CR143","doi-asserted-by":"crossref","unstructured":"Freire, P.C., et al., Specific Inhibition of the Classical Complement Pathway Prevents C3 Deposition along the Dermal-Epidermal Junction in Bullous Pemphigoid. J Invest Dermatol, 2019. 139(12):2417-2424 e2.","DOI":"10.1016\/j.jid.2019.04.025"},{"key":"832_CR144","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.jaut.2012.07.004","volume":"40","author":"PM Dias","year":"2013","unstructured":"Dias PM, Banerjee G. The role of Th17\/IL-17 on eosinophilic inflammation. J Autoimmun. 2013;40:9\u201320.","journal-title":"J Autoimmun"},{"issue":"12","key":"832_CR145","first-page":"1478","volume":"18","author":"MM Holtsche","year":"2020","unstructured":"Holtsche MM, et al. Adjuvant treatment with secukinumab induced long term remission in a patient with severe bullous pemphigoid. J Dtsch Dermatol Ges. 2020;18(12):1478\u201380.","journal-title":"J Dtsch Dermatol Ges"},{"issue":"6","key":"832_CR146","doi-asserted-by":"publisher","first-page":"e216","DOI":"10.1111\/1346-8138.14760","volume":"46","author":"M Kamata","year":"2019","unstructured":"Kamata M, et al. Secukinumab decreased circulating anti-BP180-NC16a autoantibodies in a patient with coexisting psoriasis vulgaris and bullous pemphigoid. J Dermatol. 2019;46(6):e216\u20137.","journal-title":"J Dermatol"},{"issue":"2","key":"832_CR147","doi-asserted-by":"publisher","first-page":"e155","DOI":"10.1111\/ajd.13803","volume":"63","author":"JS Yun","year":"2022","unstructured":"Yun JS, et al. Successful secukinumab treatment of active bullous pemphigoid and chronic severe psoriasis: a case report. Australas J Dermatol. 2022;63(2):e155\u20138.","journal-title":"Australas J Dermatol"},{"issue":"9","key":"832_CR148","doi-asserted-by":"publisher","first-page":"e220","DOI":"10.1111\/1346-8138.13909","volume":"44","author":"PH Ho","year":"2017","unstructured":"Ho PH, Tsai TF. Development of bullous pemphigoid during secukinumab treatment for psoriasis. J Dermatol. 2017;44(9):e220\u20131.","journal-title":"J Dermatol"},{"issue":"1","key":"832_CR149","doi-asserted-by":"publisher","first-page":"e13","DOI":"10.1111\/1346-8138.16189","volume":"49","author":"L Lu","year":"2022","unstructured":"Lu L, et al. Incidental amelioration of bullous pemphigoid during ixekizumab treatment for psoriasis. J Dermatol. 2022;49(1):e13\u20135.","journal-title":"J Dermatol"},{"key":"832_CR150","unstructured":"US National Library of Medicine, ClinicalTrials.gov. Ixekizumab in the Treatment of Bullous Pemphigoid. 2020. Available at: https:\/\/clinicaltrials.gov\/study\/NCT03099538?tab=results."},{"issue":"9","key":"832_CR151","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/nri3707","volume":"14","author":"SL Gaffen","year":"2014","unstructured":"Gaffen SL, et al. The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing. Nat Rev Immunol. 2014;14(9):585\u2013600.","journal-title":"Nat Rev Immunol"},{"issue":"5","key":"832_CR152","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1172\/JCI28508","volume":"116","author":"Y Iwakura","year":"2006","unstructured":"Iwakura Y, Ishigame H. The IL-23\/IL-17 axis in inflammation. J Clin Invest. 2006;116(5):1218\u201322.","journal-title":"J Clin Invest"},{"issue":"6","key":"832_CR153","doi-asserted-by":"publisher","DOI":"10.1111\/dth.13958","volume":"33","author":"FS Delli","year":"2020","unstructured":"Delli FS, et al. Total IgE, eosinophils, and interleukins 16, 17A, and 23 correlations in severe bullous pemphigoid and treatment implications. Dermatol Ther. 2020;33(6): e13958.","journal-title":"Dermatol Ther"},{"key":"832_CR154","doi-asserted-by":"publisher","first-page":"18001","DOI":"10.1038\/srep18001","volume":"5","author":"J Plee","year":"2015","unstructured":"Plee J, et al. Integrating longitudinal serum IL-17 and IL-23 follow-up, along with autoantibodies variation, contributes to predict bullous pemphigoid outcome. Sci Rep. 2015;5:18001.","journal-title":"Sci Rep"},{"key":"832_CR155","unstructured":"US National Library of Medicine, ClinicalTrials.gov. The Effects of Tildrakizumab in Treatment of Bullous Pemphigoid. 2020. Available at: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT04465292."},{"issue":"11","key":"832_CR156","doi-asserted-by":"publisher","first-page":"e1339","DOI":"10.1111\/jdv.19317","volume":"37","author":"C Cole","year":"2023","unstructured":"Cole C, Amber KT. Two patients with concomitant bullous pemphigoid and psoriasis successfully treated by IL-23 inhibition. J Eur Acad Dermatol Venereol. 2023;37(11):e1339\u201340.","journal-title":"J Eur Acad Dermatol Venereol."},{"issue":"6","key":"832_CR157","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1111\/bjd.12163","volume":"168","author":"Y Majima","year":"2013","unstructured":"Majima Y, et al. A successful treatment with ustekinumab in a case of antilaminin-gamma1 pemphigoid associated with psoriasis. Br J Dermatol. 2013;168(6):1367\u20139.","journal-title":"Br J Dermatol"},{"issue":"5","key":"832_CR158","doi-asserted-by":"publisher","first-page":"e228","DOI":"10.1111\/jdv.14002","volume":"31","author":"J Loget","year":"2017","unstructured":"Loget J, et al. A successful treatment with ustekinumab in a case of relapsing bullous pemphigoid associated with psoriasis. J Eur Acad Dermatol Venereol. 2017;31(5):e228\u201330.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"832_CR159","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1136\/ejhpharm-2018-001849","volume":"28","author":"M Marin","year":"2021","unstructured":"Marin M, et al. Bullous pemphigoid induced by ustekinumab: a case report. Eur J Hosp Pharm. 2021;28(1):47\u20139.","journal-title":"Eur J Hosp Pharm"},{"issue":"6","key":"832_CR160","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.jdcr.2015.07.014","volume":"1","author":"A Le Guern","year":"2015","unstructured":"Le Guern A, et al. Bullous pemphigoid during ustekinumab therapy. JAAD Case Rep. 2015;1(6):359\u201360.","journal-title":"JAAD Case Rep"},{"key":"832_CR161","unstructured":"US National Library of Medicine, ClinicalTrials.gov. Efficacy and Safety of Ustekinumab in Bullous Pemphigoid (PB-USTE). 2019; Available at: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT04117932."},{"issue":"1","key":"832_CR162","doi-asserted-by":"publisher","DOI":"10.5826\/dpc.1201a37","volume":"12","author":"D Didona","year":"2022","unstructured":"Didona D, et al. Pemphigus Vulgaris: Present and Future Therapeutic Strategies. Dermatol Pract Concept. 2022;12(1): e2022037.","journal-title":"Dermatol Pract Concept"},{"issue":"11","key":"832_CR163","doi-asserted-by":"publisher","first-page":"5512","DOI":"10.1073\/pnas.93.11.5512","volume":"93","author":"RP Junghans","year":"1996","unstructured":"Junghans RP, Anderson CL. The protection receptor for IgG catabolism is the beta2-microglobulin-containing neonatal intestinal transport receptor. Proc Natl Acad Sci U S A. 1996;93(11):5512\u20136.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"832_CR164","doi-asserted-by":"publisher","first-page":"5490","DOI":"10.1091\/mbc.e07-02-0101","volume":"19","author":"NA Goebl","year":"2008","unstructured":"Goebl NA, et al. Neonatal Fc receptor mediates internalization of Fc in transfected human endothelial cells. Mol Biol Cell. 2008;19(12):5490\u2013505.","journal-title":"Mol Biol Cell"},{"key":"832_CR165","unstructured":"US National Library of Medicine, ClinicalTrials.gov. A Phase 2\/3 Study of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid (BALLAD). 2023. Available at: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT05267600."},{"issue":"2","key":"832_CR166","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.jdermsci.2016.04.009","volume":"83","author":"H Fang","year":"2016","unstructured":"Fang H, et al. Increased expression of NLRP3 inflammasome components and interleukin-18 in patients with bullous pemphigoid. J Dermatol Sci. 2016;83(2):116\u201323.","journal-title":"J Dermatol Sci"},{"key":"832_CR167","unstructured":"US National Library of Medicine, ClinicalTrials.gov. A Proof-of-Concept Study of Topical AC-203 in Patients With Bullous Pemphigoid. 2019; Available at: https:\/\/clinicaltrials.gov\/study\/NCT03286582."},{"key":"832_CR168","unstructured":"US National Library of Medicine, ClinicalTrials.gov. Ozonated Olive Oil in Treatment of Pemphigus Vulgaris and Bullous Pemphigoid. NCT05594472. 2022 Available at: https:\/\/clinicaltrials.gov\/study\/NCT05594472."},{"key":"832_CR169","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.jdcr.2022.12.006","volume":"32","author":"D Nash","year":"2023","unstructured":"Nash D, Kirchhof MG. Bullous pemphigoid treated with Janus kinase inhibitor upadacitinib. JAAD Case Rep. 2023;32:81\u20133.","journal-title":"JAAD Case Rep"},{"issue":"10","key":"832_CR170","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15754","volume":"35","author":"Y Xiao","year":"2022","unstructured":"Xiao Y, Xiang H, Li W. Concurrent bullous pemphigoid and plaque psoriasis successfully treated with Janus kinase inhibitor Baricitinib. Dermatol Ther. 2022;35(10): e15754.","journal-title":"Dermatol Ther"},{"key":"832_CR171","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.110591","volume":"122","author":"H Li","year":"2023","unstructured":"Li H, et al. Concurrent bullous pemphigoid and psoriasis vulgaris successfully treated with Janus kinase inhibitor tofacitinib: a case report and review of the literature. Int Immunopharmacol. 2023;122: 110591.","journal-title":"Int Immunopharmacol"},{"key":"832_CR172","doi-asserted-by":"publisher","first-page":"1128154","DOI":"10.3389\/fmed.2023.1128154","volume":"10","author":"R Maglie","year":"2023","unstructured":"Maglie R, et al. The cytokine milieu of bullous pemphigoid: Current and novel therapeutic targets. Front Med (Lausanne). 2023;10:1128154.","journal-title":"Front Med (Lausanne)"}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-023-00832-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40257-023-00832-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-023-00832-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,18]],"date-time":"2024-02-18T18:08:36Z","timestamp":1708279716000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40257-023-00832-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,29]]},"references-count":172,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["832"],"URL":"https:\/\/doi.org\/10.1007\/s40257-023-00832-1","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,29]]},"assertion":[{"value":"19 November 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Aikaterini Patsatsi declares honoraria as an advisor, speaker or investigator for AbbVie, Argenx, Janssen, Pfizer, Pharmaserv Lilly, Sanofi and UCB. Meropi Karakioulaki and Kilian Eyerich declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"Open access funding provided by HEAL-Link Greece.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Writing of the manuscript, contribution to the discussion, finalization of the manuscript and approval of the submitted article: MK, KE, AP. Conception of the topic, integrity and accuracy: AP.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient Consent to Participate\/Publish"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}}]}}